Rheumatoid arthritis is treated with medications that slow or stop the immune system from attacking your joints, starting as early as possible after diagnosis. When treatment begins within the first two years of symptoms using modern therapies, remission rates can exceed 60%. Waiting longer drops that number to somewhere between 10% and 33%. The goal is straightforward: eliminate joint inflammation before it causes permanent damage.
The Treat-to-Target Approach
Modern rheumatoid arthritis care follows a strategy called treat-to-target. Your doctor measures your disease activity at regular visits and adjusts medications until you hit a specific goal. The primary target is clinical remission, meaning no significant signs or symptoms of inflammation. For people with long-standing disease where full remission proves difficult, low disease activity is an acceptable alternative goal.
This sounds simple, but it requires consistent follow-up. You’ll typically see your rheumatologist every one to three months during active disease so they can assess whether your current treatment is working. If it isn’t, they escalate to the next option rather than waiting to see if things improve on their own.
First-Line Medication
Methotrexate is the cornerstone of rheumatoid arthritis treatment and the first medication most people are prescribed. It’s taken once a week (not daily), typically starting at 7.5 mg, with your doctor increasing the dose based on your response and tolerance. Methotrexate works by broadly dialing down immune activity, which reduces the inflammation that drives joint damage. Most people also take a folic acid supplement alongside it to reduce side effects like nausea and mouth sores.
Methotrexate takes time to work. You won’t feel the full effect for several weeks, sometimes up to three months. To bridge that gap, your doctor may prescribe a short course of a corticosteroid like prednisone at a low dose for roughly 8 to 10 weeks, tapering down gradually. The steroid provides faster inflammation relief while the methotrexate builds up in your system. The key word is “short”: long-term steroid use carries its own risks, including bone thinning and weight gain, so it’s used as a temporary bridge, not a permanent solution.
What Happens if the First Treatment Doesn’t Work
Current guidelines from EULAR (the European League Against Rheumatism, updated in 2025) recommend reassessing your response after three to six months on methotrexate. If you haven’t reached your target, the next step is typically adding a biologic medication.
Biologics are a class of drugs made from living cells that block specific parts of the immune system rather than suppressing it broadly. The main types include:
- TNF inhibitors (adalimumab, etanercept, infliximab): block a protein called tumor necrosis factor that drives inflammation
- IL-6 inhibitors (tocilizumab, sarilumab): block a different inflammatory signaling molecule
- T-cell inhibitors (abatacept): prevent certain immune cells from activating
- B-cell depleters (rituximab): reduce a type of immune cell involved in the autoimmune attack
Biologics are often given alongside methotrexate, since the combination tends to work better than either alone. They’re administered by injection or infusion, depending on the specific drug. If the first biologic doesn’t work or stops working over time, your doctor can switch to another one, either from the same class or a different class entirely.
JAK Inhibitors: Effective but With Caveats
A newer category of oral medications called JAK inhibitors (tofacitinib, baricitinib, and upadacitinib) offers an alternative to biologics. These are pills rather than injections, which some people prefer. They work by blocking enzymes inside cells that transmit inflammatory signals.
However, the FDA has placed its strongest safety warning on all three approved JAK inhibitors. A large safety trial found increased risks of serious heart-related events like heart attack and stroke, blood clots, certain cancers (particularly lymphoma and, in current or past smokers, lung cancer), and death compared to TNF inhibitors. Because of these findings, JAK inhibitors are now limited to people who haven’t responded to or can’t tolerate at least one TNF inhibitor. Your doctor will weigh your individual risk factors, especially if you smoke, have cardiovascular disease, or have a history of cancer.
Exercise and Joint Protection
Medication controls the disease, but physical activity protects your function. The CDC recommends at least 150 minutes per week of moderate-intensity aerobic activity and muscle-strengthening exercises on at least two days per week. That might sound like a lot when your joints are stiff and sore, but you can break it into sessions as short as five or ten minutes.
The best activities for rheumatoid arthritis are low-impact options that don’t stress your joints: brisk walking, cycling, swimming, water exercises, tai chi, dancing, or light gardening. For strength training, choose weights or resistance bands that don’t cause joint pain. The principle is to build the muscles around your joints to provide better support, while avoiding movements that aggravate inflammation. Start slowly, pay attention to how your body responds, and increase gradually.
When Surgery Becomes an Option
If medications can’t adequately control inflammation in a particular joint, recurring bouts of swelling can erode cartilage and eventually destroy the joint. At that point, surgery may become necessary. Total joint replacement is the most effective surgical option for severe joint destruction in late-stage rheumatoid arthritis. The hip and knee are the most commonly replaced joints, since damage there directly affects your ability to walk. Joint replacement is a last resort, reserved for cases where the combination of medications and physical therapy hasn’t prevented significant structural damage and functional loss.
Why Early, Aggressive Treatment Matters
The single most important factor in long-term outcomes is how quickly effective treatment begins. Joint damage from rheumatoid arthritis can start within the first few months of the disease and is largely irreversible. People who start treatment early with a combination of methotrexate and biologics have remission rates above 60%. Those who delay treatment beyond two years or who don’t start biologics early enough see remission rates drop dramatically, to as low as 10% in some studies. The window for preventing permanent damage is narrow, and the evidence strongly favors acting quickly and escalating treatment until your inflammation is fully controlled.